Glioma Groups Based on 1p/19q, IDH , and TERT Promoter Mutations in Tumors
American Academy of Neurology · Mayo Clinic in Florida · +5 more institutions
Abstract
The prediction of clinical behavior, response to therapy, and outcome of infiltrative glioma is challenging. On the basis of previous studies of tumor biology, we defined five glioma molecular groups with the use of three alterations: mutations in the TERT promoter, mutations in IDH, and codeletion of chromosome arms 1p and 19q (1p/19q codeletion). We tested the hypothesis that within groups based on these features, tumors would have similar clinical variables, acquired somatic alterations, and germline variants.
We scored tumors as negative or positive for each of these markers in 1087 gliomas and compared acquired alterations and patient characteristics among the five primary molecular groups. Using 11,590 controls, we assessed associations between these groups and known glioma germline variants.
Citation impact
- FWCI
- 94.81
- Percentile
- 100%
- References
- 32
Authors
36- JEJeanette E. Eckel‐PassowCorresponding
American Academy of Neurology, Mayo Clinic in Florida
- DHDaniel H. Lachance
Mayo Clinic in Arizona
- AMAnnette M Molinaro
University of California, San Francisco, Neurological Surgery
- KMKyle M. Walsh
University of California, San Francisco, Neurological Surgery
- PAPaul A. Decker
Mayo Clinic in Florida
Topics & keywords
- Glioma
- Germline mutation
- Medicine
- Germline
- Somatic cell
- Mutation
- Internal medicine
- Cancer research
- Good health and well-being